For the Inventor, By the Inventor

Enter assignee name

Weesp, Netherlands

Solvay Pharmaceuticals, B.v.

USPTO Granted Patents = 67

CIPO Patents = 1

EPO Patents = 2

Forward Citations = 198

Loading Chart...

Loading Chart...

133 inventors (with patents filed for the assignee):

Cornelis G Kruse (26 out of 54 patents)

Josephus H M Lange (18 out of 25 patents)

Gustaaf J M Van Scharrenburg (14 out of 17 patents)

4. Herman H Van Stuivenberg (12 out of 18 patents)

5. Andrew C McCreary (10 out of 11 patents)

6. Bernard J Van Vliet (7 out of 11 patents)

7. Roelof W Feenstra (7 out of 13 patents)

8. Arnoldus H J Herremans (6 out of 7 patents)

9. Martinus Th M Tulp (6 out of 6 patents)

10. Hein K A C Coolen (5 out of 17 patents)

11. Axel Stoit (5 out of 15 patents)

12. Jacobus Tipker (5 out of 8 patents)

13. Willy Deleersnijder (5 out of 8 patents)

14. Michael Weske (5 out of 5 patents)

15. Wouter I Iwema Bakker (4 out of 21 patents)

Core Competencies:

Azaindole Derivatives

Dopamine Reuptake Inhibition

Heterocyclic Compounds

Muscarinic Receptors

Benzimidazolone Derivatives

Sustained Release Formulation

Transdermal Iontophoretic Delivery

Prodrugs of Piperazine

Cannabinoid Receptor Agonists

17β Hydroxysteroid Dehydrogenase Inhibitors

Adenosine Receptor Modulating Activity

Neurodegenerative Disorder Treatments

67 patents: Sort by Forward Citations

1. 8729101 - [object Object] (2014-05-20),

2. 8461184 - [object Object] (2013-06-11),

3. 8410135 - [object Object] (2013-04-02),

4. 8252930 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition (2012-08-28),

5. 8173660 - Process for the preparation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one and salts and solvates thereof (2012-05-08),

6. 8138174 - [object Object] (2012-03-20),

7. 8106056 - Combination preparations comprising bifeprunox and a dopamine agonist (2012-01-31),

8. 8106044 - [object Object] (2012-01-31),

9. 8101619 - [object Object] (2012-01-24),

10. 8084473 - Heterocyclic compounds with affinity to muscarinic receptors (2011-12-27),

11. 8067603 - Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors (2011-11-29),

12. 8063062 - [object Object] (2011-11-22),

13. 8034379 - Ion-strength independent sustained release pharmaceutical formulation (2011-10-11),

14. 7964728 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition (2011-06-21),

15. 7964604 - Bifeprunox mesylate maintenance dose compositions and methods for using the same (2011-06-21),

Solvay Pharmaceuticals, B.V. is a global pharmaceutical company focused on providing innovative solutions for the healthcare industry. With a strong emphasis on research and development, Solvay Pharmaceuticals is committed to improving the lives of patients by developing and commercializing new therapies. The company operates in various therapeutic areas including cardiovascular, central nervous system, and rare diseases. Visit our website to learn more about our healthcare and chemicals offerings in the pharmaceutical sector.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

67 Patents

#2 in Weesp

#131 in Netherlands

#10,742 in the World

Weesp, Netherlands

Solvay Pharmaceuticals, B.v.

Forward Citations = 198

133 inventors:

Cornelis G Kruse (26 out of 54 patents)

Josephus H M Lange (18 out of 25 patents)

Gustaaf J M Van Scharrenburg (14 out of 17 patents)

4. Herman H Van Stuivenberg (12 out of 18 patents)

5. Andrew C McCreary (10 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…